A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody [alemtuzumab]) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2015
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 03 Jan 2008 Trial withdrawn prior to patient recruitment as reported by ClinicalTrials.gov.
- 04 Dec 2005 New trial record.